Search research articles
Contact Us
Filters
Showing results (651-660 of 703) with videos related to
Page
of 71
Sort By:
ESMO Open
|
July 6, 2026
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer
I Schlam, D Trapani, S-E Kim, et al.
ESMO Open
|
January 4, 2025
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
E Agostinetto, G Pfeiler, D Hlauschek, et al.
The American Journal of Psychiatry
|
July 13, 2013
A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan
Murray A Raskind, Kris Peterson, Tammy Williams, et al.
ESMO Open
|
July 27, 2025
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer
R Jeselsohn, J Fu, Y Ren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2016
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Saro H Armenian, Christina Lacchetti, Ana Barac, et al.
Breast Cancer Research and Treatment
|
November 8, 2013
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
Nancy U Lin, Rachel A Freedman, Naren Ramakrishna, et al.
Biorxiv : the Preprint Server for Biology
|
May 13, 2022
Structural and functional characteristics of SARS-CoV-2 Omicron subvariant BA.2 spike
Jun Zhang, Weichun Tang, Hailong Gao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 18, 2020
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker
E L Mayer, V Abramson, R Jankowitz, et al.
Journal of the National Cancer Institute
|
May 19, 2026
Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancer
Guilherme Nader-Marta, Yue Zheng, Shoshana M Rosenberg, et al.
ESMO Open
|
July 27, 2025
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
C Corti, X Chu, P Exman, et al.
Page
of 71
Search research articles
Search
Showing results (651-660 of 703) with videos related to
Sort By:
Page
of 71
ESMO Open
|
July 6, 2026
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer
I Schlam, D Trapani, S-E Kim, et al.
ESMO Open
|
January 4, 2025
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
E Agostinetto, G Pfeiler, D Hlauschek, et al.
The American Journal of Psychiatry
|
July 13, 2013
A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan
Murray A Raskind, Kris Peterson, Tammy Williams, et al.
ESMO Open
|
July 27, 2025
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer
R Jeselsohn, J Fu, Y Ren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2016
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Saro H Armenian, Christina Lacchetti, Ana Barac, et al.
Breast Cancer Research and Treatment
|
November 8, 2013
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
Nancy U Lin, Rachel A Freedman, Naren Ramakrishna, et al.
Biorxiv : the Preprint Server for Biology
|
May 13, 2022
Structural and functional characteristics of SARS-CoV-2 Omicron subvariant BA.2 spike
Jun Zhang, Weichun Tang, Hailong Gao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 18, 2020
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker
E L Mayer, V Abramson, R Jankowitz, et al.
Journal of the National Cancer Institute
|
May 19, 2026
Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancer
Guilherme Nader-Marta, Yue Zheng, Shoshana M Rosenberg, et al.
ESMO Open
|
July 27, 2025
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
C Corti, X Chu, P Exman, et al.
Page
of 71